Genetic Basis and Therapies for Vascular Anomalies

作者：Angela Queisser, Emmanuel Seront, Laurence Myriam Boon, Miikka Vikkula · 发表于：Circulation Research · 年份：2021 · DOI：10.1161/circresaha.121.318145 · 被引用次数：241 · 研究领域：Vascular Malformations and Hemangiomas、Vascular Tumors and Angiosarcomas、Vascular Malformations Diagnosis and Treatment

Vascular and lymphatic malformations represent a challenge for clinicians. The identification of inherited and somatic mutations in important signaling pathways, including the PI3K (phosphoinositide 3-kinase)/AKT (protein kinase B)/mTOR (mammalian target of rapamycin), RAS (rat sarcoma)/RAF (rapidly accelerated fibrosarcoma)/MEK (mitogen-activated protein kinase kinase)/ERK (extracellular signal-regulated kinases), HGF (hepatocyte growth factor)/c-Met (hepatocyte growth factor receptor), and VEGF (vascular endothelial growth factor) A/VEGFR (vascular endothelial growth factor receptor) 2 cascades has led to the evaluation of tailored strategies with preexisting cancer drugs that interfere with these signaling pathways. The era of theranostics has started for the treatment of vascular anomalies. Registration: URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2015-001703-32.